Free Trial
NYSE:RFL

Rafael Q1 2025 Earnings Report

Rafael logo
$1.27 0.00 (-0.16%)
Closing price 05/6/2026 03:58 PM Eastern
Extended Trading
$1.27 +0.00 (+0.16%)
As of 05/6/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rafael EPS Results

Actual EPS
-$0.37
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Rafael Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rafael Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, December 11, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Rafael's Q3 2026 earnings is estimated for Wednesday, June 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, June 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Rafael Earnings Headlines

Rafael Holdings Insider Ups Holding By 1,810% During Year
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Rafael Holdings Inc. Wt
See More Rafael Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rafael? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rafael and other key companies, straight to your email.

About Rafael

Rafael (NYSE:RFL) primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

View Rafael Profile